Sigma-Aldrich

MilliporeSigma Launches First Software for Complete Data Traceability in Microbial Quality Control

Retrieved on: 
Mardi, mai 28, 2024
Data Management, Medical Supplies, Biotechnology, Technology, Health, Pharmaceutical, Health Technology, Apps, Applications, Software, Artificial Intelligence, Mobile, Wireless, Patient, Science, Documentation, Digital, Safety, Merck Group, Vaccine, Death, Drug discovery, DCI, Merck, Sigma-Aldrich, Multimedia, Digital reference

“Microbiological quality control labs are critical to ensuring the safety of sterile medicine. Here, the consequences of noncompliance can be very serious,” said Jean-Charles Wirth, Head of Science & Lab Solutions for the Life Science business of Merck KGaA, Darmstadt, Germany. “Our job is to offer the solution that ensures drugs are safe and brought to market to the patients who need them the most -- so data traceability is essential. Digital innovations like M-Trace® bring us one step closer to making the ‘Lab of the Future’ a reality.”

Key Points: 
  • The software increases overall process safety by automatically documenting data for every step of the testing process.
  • View the full release here: https://www.businesswire.com/news/home/20240528934576/en/
    Operator using M-Trace® Electronic Test Record Software (Photo: Business Wire)
    “Microbiological quality control labs are critical to ensuring the safety of sterile medicine.
  • “Our job is to offer the solution that ensures drugs are safe and brought to market to the patients who need them the most -- so data traceability is essential.
  • Some of these technologies include AI-powered software pieces focused on digital chemistry and drug discovery, like AIDDISON™ AI powered drug discovery software and SYNTHIA™ Retrosynthesis Software.

Thrive Bioscience Welcomes Todd Lewis as Chief Commercial Officer

Retrieved on: 
Jeudi, mai 16, 2024
Software, Growth, Regenerative medicine, Sigma-Aldrich, Research, Drug discovery, Infection, Management

BEVERLY, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Thrive Bioscience, Inc., a provider of innovative automated live cell imaging instruments and software, is pleased to announce that Todd Lewis has joined the executive management team as its Chief Commercial Officer.

Key Points: 
  • BEVERLY, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Thrive Bioscience, Inc., a provider of innovative automated live cell imaging instruments and software, is pleased to announce that Todd Lewis has joined the executive management team as its Chief Commercial Officer.
  • Prior to joining Thrive, Lewis was instrumental in expanding sales globally and building commercial operations at several top-tier life science companies.
  • “I am incredibly excited to join Thrive, leading the commercial team to further our mission of delivering advanced imaging platforms to researchers,” said Todd Lewis.
  • I am thrilled for Todd to join our executive leadership team and help us bring Thrive to the next level on our growth trajectory.”

MilliporeSigma Signs Definitive Agreement to Acquire Mirus Bio, Furthering Ambition to Be a Leading Supplier for Viral Vector Manufacturing

Retrieved on: 
Mercredi, mai 22, 2024
Medical Supplies, Biotechnology, Manufacturing, Health, Pharmaceutical, Research, Other Manufacturing, Infectious Diseases, Genetics, Science, Clinical Trials, Patient, Mirus Bio, Transfection, Merck Group, Buffer, Growth, Acquisition, Merck, Sigma-Aldrich, Lentivirus, Multimedia, CDMO, Enzyme, Fine chemical

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, today announced the signing of a definitive agreement to acquire Mirus Bio for US$ 600 million.

Key Points: 
  • MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, today announced the signing of a definitive agreement to acquire Mirus Bio for US$ 600 million.
  • Transfection reagents play a critical role in the production of viral vector-based gene therapies.
  • Its expertise and portfolio covers a variety of viral vector types, including adeno-associated virus, lentivirus, and adenovirus.
  • This deal is anticipated to close in Q3 of 2024 and is subject to regulatory clearance and other customary closing conditions.

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results

Retrieved on: 
Jeudi, mai 9, 2024
Biotechnology, Neurology, Health, Genetics, Pharmaceutical, STAC, FDA, CTA, Haemophilia, Enzyme replacement therapy, Kite, Investment, Nav1.7, Fabry disease, Poster, Disease, ERT, Sigma-Aldrich, STAAR, Health care, MAA, Partnership, Sangamo Therapeutics, MINT, AAV, Ligand Pharmaceuticals, IND, Tauopathy, Novartis, DNA, Patient, Pivotal, DSM-IV codes, EMA, Prion, BBB, Genome, BLA, MHRA, Manuscript, BioRxiv, Capsid, Modularity, Biogen, Therapy, Food and Drug Administration, European Medicines Agency, Gene, Pharmaceutical industry

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported business highlights and first quarter 2024 financial results.

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported business highlights and first quarter 2024 financial results.
  • “We are pleased with the progress being made in business development discussions across our portfolio, including our Fabry disease program.
  • An IND submission is expected in the fourth quarter of 2024.
  • Revenues for the first quarter ended March 31, 2024 were $0.5 million, compared to $158.0 million for the same period in 2023.

Scorpius Holdings Appoints New VP of Business Development Shari Udoff-McDonald

Retrieved on: 
Mardi, mai 7, 2024
Commercial, Sigma-Aldrich, Business development, Vaccine, CDMO, Scorpius, Marketing, Messenger, GMP, Spacecraft

DURHAM, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX) (“Scorpius” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced the appointment of Shari Udoff-McDonald as VP of Business Development.

Key Points: 
  • DURHAM, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX) (“Scorpius” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced the appointment of Shari Udoff-McDonald as VP of Business Development.
  • She brings more than 25 years of experience in biopharma business development and management.
  • Joe Payne, Scorpius’ President and COO, said, “Shari has the unique combination of experience in the field, at the account-level, and in leadership roles.
  • This wide breadth of business development experience will help Scorpius continue to grow its customer base.

NIIMBL announces 63 students for the 2024 NIIMBL eXperience

Retrieved on: 
Mardi, avril 30, 2024
University, Museum, Outline of health sciences, Experience, Sigma-Aldrich, Eli Lilly, North Carolina State University, Student, JIB, Santa Clara University, NIIMBL, Thomas Jefferson University, BTEC, Merck, University of Houston, Growth, Management

NEWARK, Del., April 30, 2024 /PRNewswire/ -- The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is pleased to announce 63 students from 41 academic institutions have been selected to take part in the 2024 NIIMBL eXperience, the largest cohort since the Program's launch in 2019.

Key Points: 
  • NEWARK, Del., April 30, 2024 /PRNewswire/ -- The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is pleased to announce 63 students from 41 academic institutions have been selected to take part in the 2024 NIIMBL eXperience, the largest cohort since the Program's launch in 2019.
  • The NIIMBL eXperience is a week-long, all-expenses-paid immersion program designed to introduce underrepresented groups including Black, Latinx, and Indigenous students completing their first or second year of college to career possibilities in the biopharmaceutical industry.
  • "The NIIMBL eXperience has been a cornerstone of our efforts to expand and diversify talent pipelines for the biopharmaceutical industry," said John Balchunas, NIIMBL Workforce Director.
  • Since 2019, the NIIMBL eXperience has served 80 students from 69 different academic institutions.

Particle Dynamics Appoints New CFO as it Advances its Strategic Growth Plans

Retrieved on: 
Mardi, avril 23, 2024
Health Technology, Pharmaceutical, Health, Sigma-Aldrich, Microsoft Dynamics 365, Merck Group, Particle, OSD, Knowledge, Avadel Pharmaceuticals, Growth, Strategic planning, Management

Mike's appointment marks a significant milestone for Particle Dynamics, underscoring the company’s commitment to delivering enhanced value to clients and stakeholders.

Key Points: 
  • Mike's appointment marks a significant milestone for Particle Dynamics, underscoring the company’s commitment to delivering enhanced value to clients and stakeholders.
  • His proven track record in financial leadership and strategic planning will be instrumental in driving Particle Dynamics’ continued growth and success in the pharmaceutical and healthcare industries.
  • Nicolas Fortin, CEO of Particle Dynamics, said: “Mike’s extensive experience and financial leadership make him the ideal candidate to lead our finance team during this exciting period of growth and expansion.
  • I am confident Mike’s strategic vision will be invaluable as we continue to strengthen our position as a global leader in particle processing and delivery technologies."

NeoGenomics Announces Senior Leadership Promotions

Retrieved on: 
Jeudi, avril 18, 2024
Medical Devices, Hospitals, Genetics, Health Technology, Biotechnology, Other Health, Health, General Health, Oncology, Harvard Law School, Suffolk University, University, Political science, LIMS, Sigma-Aldrich, Ortho Clinical Diagnostics, Senior, JD, Qualcomm, SomaLogic, NEO, Marketing, Rock (geology), MBA, Growth, Management

NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced two promotions within its senior leadership team, effective immediately.

Key Points: 
  • NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced two promotions within its senior leadership team, effective immediately.
  • “Warren and Melody have shown exceptional leadership and performance in their respective roles," said Chris Smith, CEO of NeoGenomics.
  • “As we enter our next phase of growth, these senior leadership appointments should drive operational efficiencies, strengthen commercial synergies, and accelerate innovation through R&D.
  • Prior to NeoGenomics, Stone served as President of Americas at Ortho Clinical Diagnostics and Senior Vice President, Life Sciences Division for MilliporeSigma.

MilliporeSigma Inspires Students to Explore STEM Careers with 2024 Curiosity Cube Tour

Retrieved on: 
Mercredi, avril 17, 2024
Education, Science, Other Science, Primary, Secondary, Merck Group, Sigma-Aldrich, Student, Transformation, Multimedia, Merck, Tourism

MilliporeSigma’s goal is to engage 45,000 students to increase access to hands-on STEM education for students through interactive science experiences.

Key Points: 
  • MilliporeSigma’s goal is to engage 45,000 students to increase access to hands-on STEM education for students through interactive science experiences.
  • View the full release here: https://www.businesswire.com/news/home/20240417283942/en/
    MilliporeSigma Inspires Students to Explore STEM Careers with 2024 Curiosity Cube Tour (Photo: Business Wire)
    “Recent data shows students between 8 and 13 years old are interested in science and math, with most calling these subjects fun and exciting.
  • Students also meet our employees, who can be role models for the incredible range of STEM careers that are possible.”
    For the 2024 tour, the Curiosity Cube is sporting a new look, displaying photos of young scientists who are children of MilliporeSigma employees.
  • To learn more about the Curiosity Cube mobile science lab and view the 2024 tour schedule, visit TheCuriosityCube.com and follow the Curiosity Cube on Instagram @curiositycube_milliporesigma.

MilliporeSigma Launches First All-in-One Genetic Stability Assay to Accelerate Biosafety Testing

Retrieved on: 
Mardi, avril 16, 2024
Biotechnology, Pharmaceutical, Health, FDA, Merck Group, Investment, Risk, Sigma-Aldrich, Software suite, Automation, Multimedia, GMP, Merck

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, launched the first all-in-one, validated genetic stability assay of its kind.

Key Points: 
  • MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, launched the first all-in-one, validated genetic stability assay of its kind.
  • The Aptegra™ CHO genetic stability assay leverages whole genome sequencing and bioinformatics to significantly accelerate biosafety testing for clients and therefore, their move into commercial production.
  • The Aptegra™ platform transforms biosafety testing with a digital solution using next-generation sequencing.”
    Currently, FDA guidance requires biotech companies to use multiple assays to address genetic stability requirements.
  • Its global biosafety testing network includes sites in Shanghai, China; Singapore; Stirling and Glasgow, UK; and Rockville, MD, USA.